![Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK562120/bin/493434_1_En_1_Fig3_HTML.jpg)
Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf
![Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma [PeerJ] Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2022/12646/1/fig-2-full.png)
Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma [PeerJ]
![Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/356259194/figure/fig2/AS:1091002400022593@1637126650745/Overall-survival-plot-Kaplan-Meier-curve-is-shown-for-overall-survival-in-patients-with.png)
Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram
![Kaplan-Meier overall survival curve. The median overall survival was... | Download Scientific Diagram Kaplan-Meier overall survival curve. The median overall survival was... | Download Scientific Diagram](https://www.researchgate.net/publication/325775075/figure/fig3/AS:659702010617873@1534296624892/Kaplan-Meier-overall-survival-curve-The-median-overall-survival-was-170-days-95-CI.png)
Kaplan-Meier overall survival curve. The median overall survival was... | Download Scientific Diagram
![Time Trends of Overall Survival and Survival after Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer - Journal of Thoracic Oncology Time Trends of Overall Survival and Survival after Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040423073/2053914276/gr1.jpg)
Time Trends of Overall Survival and Survival after Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer - Journal of Thoracic Oncology
![Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f202d504-2f19-493f-b3f6-b0e9f416627d/gr1.jpg)
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell
![Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - European Journal of Cancer Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b98b535c-9b9a-45ed-bc17-fc425a85d6bb/gr1_lrg.jpg)
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - European Journal of Cancer
![Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis](https://jcancer.org/v09/p3156/jcav09p3156g005.jpg)
Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
![Validation of an assessment tool: Estimation of Postoperative Overall Survival for Gastric Cancer - European Journal of Surgical Oncology Validation of an assessment tool: Estimation of Postoperative Overall Survival for Gastric Cancer - European Journal of Surgical Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/36478a24-f62d-4c3f-bdbe-2fb076234186/gr1_lrg.jpg)
Validation of an assessment tool: Estimation of Postoperative Overall Survival for Gastric Cancer - European Journal of Surgical Oncology
![Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Annals of Oncology Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ad9b540e-d891-4d45-a088-67c7de8c0dd8/gr1_lrg.jpg)
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Annals of Oncology
![Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0061-6/MediaObjects/41416_2018_61_Fig1_HTML.jpg)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
![Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram](https://www.researchgate.net/publication/312548097/figure/fig1/AS:616359859863564@1523963050372/Overall-survival-The-Kaplan-Meier-graph-shows-overall-survival-of-the-entire-patient.png)
Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram
![Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis](https://jcancer.org/v09/p3156/jcav09p3156g008.jpg)
Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis
![The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma - Radiotherapy and Oncology The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma - Radiotherapy and Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e6e822ee-76a0-4a9b-8f2c-30f0943e1f1c/gr1_lrg.jpg)
The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma - Radiotherapy and Oncology
![Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC - Journal of Hepatology Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC - Journal of Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3d9a132c-edbc-440e-a663-6fb023ee8a6a/fx1_lrg.jpg)